← Back to Screener
Oncolytics Biotech, Inc. Common Shares (ONCY)
Price$0.84
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)27.18%
Price vs S&P 500 (4W)-3.38%
VGM Score78.37
Market Capitalization$123.07M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)7.04x
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)199.82%
EPS (TTM)$-0.27
10-Day Avg Trading Volume0.25M
EPS Excl Extra (TTM)$-0.27
EPS (Annual)$-0.30
ROI (Annual)-449.98%
Cash / Share (Quarterly)$0.12
ROA (Last FY)-157.08%
EBITD / Share (TTM)$-0.27
ROE (5Y Avg)-177.65%
Cash Flow / Share (Annual)$-0.24
P/B Ratio28.12x
P/B Ratio (Quarterly)15.17x
Net Income / Employee (Annual)$-785,835
Net Interest Coverage (TTM)-1311.50x
ROA (TTM)-144.60%
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)2.82x
Quick Ratio (Quarterly)2.40x
3-Month Avg Trading Volume0.29M
52-Week Price Return12.82%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.98
P/S Ratio (Annual)552.37x
Asset Turnover (Annual)0.01x
52-Week High$1.85
EPS Excl Extra (Annual)$-0.30
CapEx CAGR (5Y)88.66%
Tangible BV CAGR (5Y)-14.52%
26-Week Price Return32.71%
Quick Ratio (Annual)2.54x
13-Week Price Return155.86%
Total Debt / Equity (Annual)0.18x
Current Ratio (Quarterly)2.88x
Enterprise Value$120.79M
Book Value / Share Growth (5Y)-26.82%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1206.45%
Cash / Share (Annual)$0.15
3-Month Return Std Dev133.96%
Net Income / Employee (TTM)$-753,709
ROE (Last FY)-530.00%
Net Interest Coverage (Annual)-33.16x
EPS Basic Excl Extra (Annual)$-0.30
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-0.27
Receivables Turnover (Annual)0.00x
ROI (TTM)-384.49%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.45
Price vs S&P 500 (52W)14.17%
Year-to-Date Return208.70%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-83.59%
Net Profit Margin (Annual)-1164.52%
Month-to-Date Return1.43%
Cash Flow / Share (TTM)$-0.36
EBITD / Share (Annual)$-0.32
Operating Margin (Annual)-1206.45%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-160.53%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.27
P/TBV (Quarterly)21.79x
P/B Ratio (Annual)17.13x
Book Value / Share (Annual)$0.05
Price vs S&P 500 (13W)145.14%
Beta0.84x
Revenue / Share (TTM)$0.00
ROE (TTM)-440.39%
52-Week Low$0.45
mGradeB
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.88
3.88
3.88
3.88
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ONCYOncolytics Biotech, Inc. Common Shares | — | — | B | $0.84 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Oncolytics Biotech is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. Its lead candidate, pelareorep, enhances immune response to make tumors more susceptible to existing oncology treatments. The company's pipeline includes programs targeting breast cancer and gastrointestinal cancers across multiple indications.